This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A whitepaper has outlined a pathway that could allow Italy to realise the potential of digital therapeutics (DTx). The official journal of the Smith Kline Foundation, Tendenze Nuove, has published the paper entitled “Digital Therapeutics, an Opportunity for Italy” earlier this month.
This shift in approach to validation aims to realign effort to planning and preparation first, then defining the testing to be performed, and finally test execution and documentation. Download WhitePaper To download this whitepaper, complete the form below. Leave this field blank
To learn more about how the 3M Harvest RC Chromatographic Clarifier is revolutionising biopharma production, download this specially commissioned whitepaper. “This can result in reductions in costs for our customers.”
From cave paintings to emails, we now communicate faster, clearer, and from greater distances. From cave paintings to emails, we now communicate faster, clearer, and from greater distances. Download WhitePaper To download this whitepaper, complete the form below. Leave this field blank Quality Validation
In 2020, the FDA released a guidance document for the industry with recommendations for sponsors developing gene therapies for rare diseases. This document delved into aspects related to manufacturing, preclinical, and clinical trial design for all phases of clinical development.
Introducing EU Annex 1: Understanding the Newest Regulatory Requirements Trudy Patterson Sat, 07/01/2023 - 06:00 WhitePaper — Sponsored Content Introducing EU Annex 1: Understanding the Newest Regulatory Requirements 1 July 2023 As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products.
A whitepaper on regulatory development for low- to middle-income countries, international collaboration on methods for producing gene therapies, and public/private partnerships to support therapies for extremely rare disorders are other steps to consider. All see such initiatives as an opportunity to learn from other regulators.
To learn more about the 3M TM Harvest RC Chromatographic Clarifier and the efficiencies achievable in biopharma manufacturing, download the specially commissioned whitepaper on this page. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
While remote communication with HCPs rose in all countries in the same time period, not all remote engagement was the type likely to be described as meaningful – much of the volume was in emails, with WhatsApp, and other remote messaging, also important during the peak infection period.
To learn more about the ways that the 3MTM Harvest RC Chromatographic Clarifier can increase efficiencies in the production of mAb therapies, download this specially commissioned whitepaper. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
and management communication strategy. ™” is becoming an increasingly rhetorical one, particularly in view of the growing momentum in the pharmaceutical industry and in various statements and whitepapers from key regulatory agencies. Is the vendors’ documentation complete in order to assess GxP risks and GxP compliance?
Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a whitepaper describing the content and format of an improved Module 2.
Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a whitepaper describing the content and format of an improved Module 2.
Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. Other medical information.
For changes requiring approval before implementation, once the necessary information has been submitted across regions, each health authority must review the data package and documentation based on local requirements. laboratory notebooks, batch records, and technical reports) to submission documents (e.g., doi:10.1016/j.xphs.2021.09.046.
Nature Communications 12, no. Subsequently, the new data is authored into Module 3 (Quality) of the Common Technical Document and submitted separately to multiple health authorities worldwide for approval. EFPIA WhitePaper on CMC Development, Manufacture and Supply of Pandemic COVID-19 Therapies and Vaccines.”
13 An FDA-authored paper indicating support for the implementation of CM using science- and risk-based approaches followed soon thereafter. Due to the expanding workload of the ETP, CDER has begun implementing ETP program enhancements to improve strategy and operation and to enhance communication with those adopting new technologies.
According to the legal documents , the plaintiffs accused the companies of “violating federal antitrust laws, alleging “per se” and “rule of reason” violations”. Gilenya is an oral medication for multiple sclerosis. Please check your email to download the Report.
To find out more about Pall’s specialist filters and the services available in water safety, download the whitepaper on this page. This document will explain the dangers associated with waterborne bacteria and the importance of a Holistic Water Safety Plan. Please check your email to download the Brochure.
To learn more, download the document below. model, download this whitepaper. Through its Maggie family of autoinjectors, SHL is working with its partners to advance the device development side of combination products, together gaining key competitive edges in this burgeoning subcutaneous drug delivery market. References 1.
The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Integrated logistics and quality data is documented automatically, and operators can spend less time chasing status, progress and performance data from multiple sources. In supply chains involving 10,000s of point-of-use destinations and stakeholders distributed across the world, one-to-one communications are not sufficient.
In addition, several pieces of documentation will be required to support the API qualification, e.g. pharmacopeial compliance. It is also essential to evaluate the reliability of the company supplying the ingredient: do they provide sufficient communication and documentation?
To learn more about the development and partnership opportunities for businesses within Scotland’s health sector, download the document on this page. Free Whitepaper. Precision Medicine: Streamlining Treatments and Drug Development. Please check your email to download the Whitepaper.
While not binding, the document covers the regulatory and scientific considerations needed for the development and implementation of continuous manufacturing in pharma, and the guidelines are meant for both new and pre-existing products. Funding was also given to companies that would bolster US-based production of critical medicines.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content